BIOTECHNOLOGY VALUE FUND II LP
CIK 1102444 · last filed 2026-06-26
BIOTECHNOLOGY VALUE FUND II LP is a corporate insider who has filed 46 SEC Form 4 insider transactions across 20 companies since 2008. The most recent filing shows the insider sold $1.74B of KYMR on Jun 26, 2026. Across all open-market trades the lifetime net is −$1.15B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.33B across reported positions. The firm reports its address in San Francisco, CA. 509 SEC filings were submitted jointly with BIOTECHNOLOGY VALUE FUND L P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.33B
20
46
-$1.15B
Filer Profile
40TH FL
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 1,671,048 | $114.96 | $192.10M | -$1.43B | 4 | 2026-06-26 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 62,383 | $15.70 | $979.4K | $0 | 1 | 2025-06-17 | |
| MLTX | Director | 10,235,089 | $12.51 | $128.04M | $0 | 1 | 2025-06-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,792,157 | $2.65 | $10.05M | $28.21M | 1 | 2023-11-03 | |
| RAIN | 1,479,460 | $0.74 | $1.09M | $21.20M | 3 | 2021-09-23 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 4,336,875 | $38.00 | $164.80M | $33.14M | 2 | 2020-10-08 | |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 1,948,819 | $40.17 | $78.28M | $21.66M | 6 | 2020-09-01 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 3,927 | $13.60 | $53.4K | -$1.57M | 1 | 2019-09-10 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,372,596 | $0.04 | $284.9K | $20.07M | 2 | 2018-11-21 |
| SNDX | 85,038 | $18.18 | $1.55M | $0 | 1 | 2018-06-20 | |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 1,898,293 | — | — | $3.08M | 4 | 2015-02-09 | |
| CCXI | 485,412 | $12.32 | $5.98M | $11.62M | 1 | 2013-09-13 | |
| NBIX | 756,600 | $156.22 | $118.20M | $2.48M | 1 | 2011-10-12 | |
| CAPS | 952 | $0.18 | $173 | $1.55M | 2 | 2011-08-22 | |
| Celera CORP (CRA) Delisted | 31,520,834 | — | — | $155.25M | 4 | 2011-05-10 | |
| AVIGEN INC \DE (AVGN) Delisted | 15,674,378 | — | — | -$5.6K | 1 | 2009-11-20 | |
| RPRX | 2,145,776 | $58.61 | $125.76M | -$3.60M | 1 | 2009-09-24 | |
| CRIS | 4,097 | $1.13 | $4.6K | -$17.08M | 1 | 2009-04-29 | |
| LGND | 10%+ Owner | 2,663,034 | $284.47 | $757.55M | $5.66M | 5 | 2009-01-27 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 8,135,099 | — | — | $773.0K | 1 | 2008-11-12 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | KYMR | Sell (S) | −16,306,580 | -$1.74B | EDGAR |
| 2026-01-30 | — | U | −101,669,430 | $0 | |
| 2025-10-14 | — | U | −114,816,850 | $0 | |
| 2025-06-17 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Other (J) | +12,700,040 | $0 | EDGAR |
| 2025-06-09 | MLTX | Grant (A) | — | $0 | EDGAR |
| 2023-11-03 | Repare Therapeutics Inc. (RPTX) Delisted | Buy (P) | +7,837,090 | $28.21M | EDGAR |
| 2022-01-31 | KYMR | Buy (P) | +1,303,090 | $50.76M | EDGAR |
| 2021-09-23 | RAIN | Buy (P) | +110,330 | $1.54M | EDGAR |
| 2021-07-06 | KYMR | Buy (P) | +5,441,660 | $255.76M | EDGAR |
| 2021-06-21 | KYMR | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.